Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) analyst actions
Rating and price-target actions on ATNM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ATNM overview →
2 measured ATNM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program | Press release | +4.82% | -4.82% | |
| Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML | Press release | -0.90% | +3.60% |
Keep exploring
More ATNM: earnings → · SEC filings → · ATNM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Second Sight Medical Products, Inc. (EYES) | 788 | -0.56% | 34% |
| bluebird bio, Inc. (BLUE) | 787 | -0.01% | 46% |
| Heat Biologics, Inc. (HTBX) | 781 | -0.40% | 41% |
| HEMISPHERX BIOPHARMA (HEB) | 779 | -0.06% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.